TME Pharma N.V. Logo

TME Pharma N.V.

Developing therapies for aggressive cancers by neutralizing the tumor microenvironment.

ALTME | Euronext Growth

Overview

Corporate Details

ISIN(s):
NL0015000YE1 (+1 more)
LEI:
724500EPNADXWZ58U595
Country:
Germany
Address:
Max-Dohrn-Strasse 8-10, 10589 Berlijn
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

TME Pharma N.V. is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of aggressive cancers. The company specializes in targeting the tumor microenvironment (TME). Its proprietary technology aims to neutralize chemokines within the TME, thereby breaking tumor protection barriers against the immune system and blocking tumor repair mechanisms. This approach is designed to be used in combination with other treatments to weaken tumor defenses and enhance overall therapeutic efficacy. The company's clinical pipeline includes programs for glioblastoma and pancreatic cancer, with its lead candidate, NOX-A12, showing promising results in clinical trials.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-18 08:00
Regulatory News Service
Inside Information / Other news releases
English 255.7 KB
2025-06-18 08:00
M&A Activity
Informations privilégiées / Autres communiqués
French 287.8 KB
2025-05-27 08:00
Capital/Financing Update
Inside Information / Other news releases
English 386.1 KB
2025-05-27 08:00
Capital/Financing Update
Informations privilégiées / Autres communiqués
French 388.7 KB
2025-05-26 08:00
Pre-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 261.4 KB
2025-05-26 08:00
Pre-Annual General Meeting Information
Inside Information / Other news releases
English 222.6 KB
2025-05-21 08:00
Capital/Financing Update
Informations privilégiées / Autres communiqués
French 329.1 KB
2025-05-21 08:00
Capital/Financing Update
Inside Information / Other news releases
English 286.1 KB
2025-05-05 18:00
Director's Dealing
Inside Information / Other news releases
English 243.3 KB
2025-05-05 18:00
Director's Dealing
Informations privilégiées / Autres communiqués
French 255.1 KB
2025-05-05 08:00
Board/Management Information
Inside Information / Other news releases
English 281.1 KB
2025-05-05 08:00
Board/Management Information
Informations privilégiées / Autres communiqués
French 287.8 KB
2025-04-25 18:00
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 351.1 KB
2025-04-25 18:00
Earnings Release
Inside Information / News release on accounts, results
English 275.9 KB
2025-04-10 19:00
Regulatory News Service
Informations privilégiées / Autres communiqués
French 224.0 KB

Automate Your Workflow. Get a real-time feed of all TME Pharma N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for TME Pharma N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea 394800
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea 174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea 203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea 298380
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France ALACT
Adecco Group AG Logo
Global talent solutions firm offering staffing, placement, career transition, and tech consulting.
Switzerland ADI1
ADforus Co., Ltd. Logo
Ad-tech firm with AI platforms for mobile marketing and publisher monetization solutions.
South Korea 397810
Adocia Logo
Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.
France ADOC
ad pepper media International N.V. Logo
Global performance marketing & audience targeting solutions for advertisers and agencies worldwide.
Germany APM

Talk to a Data Expert

Have a question? We'll get back to you promptly.